Project Grant HT94252510518
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$545K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award of $613,125.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...
The University of Texas Health Science Center at Houston was awarded a $1.25 million project grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research on peptides targeting metastatic tumor cells. The three-year award, made on September 1, 2022, will support the development of peptides as probes for cancer detection and delivery vehicles for cancer therapy. Through basic, applied, and advanced biomedical research, the...
This Project Grant award of $160,167.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a peptide drug conjugate as a bone-targeted therapy for bone metastatic prostate cancer. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, and will fund research activities at the cancer center from September 1, 2023 through August 24, 2024. The project...
The University of Texas Health Science Center at San Antonio received a $1,565,298 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) on September 1, 2025. The grant will support research to target the METTL3 protein and overcome drug resistance in metastatic clear cell renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative, advanced...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The University of Texas Health Science Center at Houston was awarded a $938,597 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research on peptides targeting metastatic tumor cells as probes for cancer detection and vehicles for therapy delivery. The three-year award beginning September 1, 2022 will support the development of new biomedical technologies using metastatic tumor-targeting peptides to...
This federal Project Grant award of $1,354,543.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports a Phase 1 clinical trial of an engineered oncolytic HSV-1 M032 virus for the treatment of newly diagnosed diffuse midline glioma. The award was made on August 1, 2025 to The University of Texas M.D. Anderson Cancer Center, a premier academic cancer research and treatment institution, and is scheduled for completion by July 31,...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
The federal Project Grant award of $1,496,576.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Baylor College of Medicine in Houston, Texas, aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational domains, will focus on innovative investigations across multiple medical...